Dermavant Sciences, a biopharmaceutical company focused on delivering therapies for dermatologic conditions, has added four new members to its executive team, it was reported yesterday.
David Rubenstein, GlaxoSmithKline's former vice president, discovery and preclinical development, joins the group as its new chief scientific officer. Prior to GSK, he held academic roles at the University of North Carolina. In addition to Rubenstein, Richard Peterson joins the biopharma as its chief financial officer. Peterson, who earlier worked at Sienna Biopharmaceuticals as its chief financial officer, comes to Dermavant Sciences with experience in the dermatology space. He has previously served as chief financial officer for Novan and chief financial officer, executive vice president of Medicis Pharmaceutical Corporation.
Ariel Jasie has been named as the new chief business and strategy officer. Jasie has joined the biopharma from Codiak BioSciences, where he served as chief business officer and prior to that, he served in various executive roles at Celgene, most recently as executive director for strategy and operations. Chris Van Tuyl has joined the company as general counsel. He has earlier served in numerous positions, including corporate secretary, chief compliance officer and associate general counsel at Rayonier, where he oversaw key aspects of the company's spinoff of its chemical business in 2014.
Convergent Therapeutics names new chairman of board of directors
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Cardinal Health names new independent director
Micron Biomedical names new scientific advisor to CEO
MedPharm names new executive chairman
Armonica Technologies names new director
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Ardigen names new chief commercial officer
AbbVie names new chief executive officer
AMO Pharma collaborates with Population Health Research Institute for tideglusib clinical trial